Phase II trial of combination therapy with oxaliplatin and capecitabine in patients with advanced esophageal cancer.
Completed
- Conditions
- Esophageal cancer.
- Registration Number
- NL-OMON20867
- Lead Sponsor
- /A
- Brief Summary
Br J Cancer. 2007 May 7;96(9):1348-52. Epub 2007 Apr 17.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 43
Inclusion Criteria
Metastatic or local-regional unresectable adenocarcinoma or squamous cell carcinoma esophagus or gastric junction, at least one unidimensional measurable lesion > 20mm (conventional), > 10mm (spiral), WHO 0-2, adequate hematological, renal and hepatic functions.
Exclusion Criteria
Prior treatment with oxaliplatin or capecitabine;
prior (neo)adjuvant treatment for metastatic disease is allowed if completed at least 6 months prior to study start. malabsorption syndrome or inability to take oral medication, pre-existing motor or sensory neurotoxicity grade >1, active infection.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method